Skip to main content
Premium Trial:

Request an Annual Quote

PerkinElmer Closes Acquisition of Pediatrix's Newborn Screening Business

NEW YORK (GenomeWeb News) – PerkinElmer said Friday that it has completed its acquisition of the newborn metabolic screening business of Pediatrix Medical Group.
The company announced its plans to acquire the business in December in a bid to expand its presence in the neonatal health market.
The acquisition gives PerkinElmer Pediatrix's screening reference laboratory and its StepOne newborn screening product, which analyzes more than 50 inherited disorders in newborns.
The Pediatrix screening lab offers services to hospitals and medical groups in Maryland, Mississippi, Louisiana, Nebraska, Pennsylvania, and the District of Columbia.
PerkinElmer did not disclose the financial terms of the acquisition, but according to a purchase agreement dated Dec. 18, 2007 and filed with the US Securities and Exchange Commission on Feb. 28 as part of its annual report, PerkinElmer planned to pay $66 million to acquire the business.
PerkinElmer said in December that Pediatrix’s screening business generated revenues of around $15 million in 2007.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.